We report an interesting case in whom fluctuating thyroid dysfunction developed following irradiation of the neck for the radical treatment of Hodgkin's disease.
Case report
In 1974 a 33-year-old male Caucasian presented with enlarged lymph nodes in the left axilla, the biopsy of which confirmed the diagnosis of lymphocyte predominant Hodgkin's disease. His chest X-ray and lymphogram were normal, but a staging laparotomy revealed splenic involvement. He was considered to have stage IlIA disease as he had no systemic symptoms and, according to the protocol used at that time, was treated with total nodal irradiation which involved applying so-called 'mantle' fields to the upper trunk to include the neck, axilla and mediastinum. In the radiation field a tumour dose of 35 Gy was delivered in 20 daily treatments in an overall time of28 days on a Cobalt unit, followed by a similar dose to the para-aortic and inguinal region after a short interval. The lungfields were protected with lead screening and a funnel-shaped lead shield was used to protect the oral cavity, larynx and thyroid isthmus. The remission of disease was complete and the patient remains recurrence-free 13 years later.
Two years after receiving radiotherapy it was noted that the patient was gaining weight and he was complaining of constipation. Clinically he appeared to be developing myxoedema and thyroid function tests confirmed a diagnosis of hypothyroidism (T4 20 nmol/l (normal range 50-150». The patient commenced treatment with thyroxine 0.1 mg three times. daily and rapidly became euthyroid; he remained well for 6 years until 1982, when he presented with sweating attacks and weight loss. Further investigations revealed no evidence of a recurrence of the Hodgkin's disease. The patient subsequently developed clinical exophthalmos and his T 4 became elevated at 245 nmolll, T s 5.4 nmolll (normal range 1.5-3.1) and he had a thyroidstimulating hormone (TSH) level of 1.8 mUll (normal range 0-10). His thyroxine replacement was reduced to 0.1 mg daily and carbimazole 15 mg three times daily was started.
The patient's condition improved and he remained well for 6 months, when he again presented with
Discussion
The effects of ionizing radiation on the thyroid gland may lead to a variety of clinical syndromes including the induction of neoplasia and autoimmune disease-s.
Post-irradiation hypothyroidism has been des-crib~~3-5" and it~prevalence in lymphoma patients recervmg mantle field irradiation of 20-40 Gy appears to fall between 10% and 20%. The time of onset of hypothyroidism following irradiation has been shown to be related to the dose of radiation given, as a lower dose will predispose to a later onset of myxoedema".
It is possible that radiation-induced hypothyroidism is a manifestation of an organ-specific autoimmune disorder, as the pathological damage to the thyroid has been shown to produce epithelial injury and necrotizing vasculitis and thrombosis". It is thought that the release of thyroid cellular components may act as the 'triggering' antigenic stimulus for the induction of cell-specific autoantibodies and the initiation of the autoimmune disease process. In order for this mechanism to produce sustained release of antibody on single contact with antigen, a genetic susceptibility must be present. It has been shown in the mouse that an immune response genetic locus (Ir-I) lies within the major histocompatibility locus and determines the sustained production of antibody following antigenic stimulation", In man, an association between the spontaneous development of Graves' disease and HL-A8 has been demonstrated", Further evidence for this theory is given by Tamura et al. 5 who demonstrated raised thyroid antibody titres in 4~f 6 patients who subsequently became hypothyroid following irradiation during lymphoma treatment. . Hyperthyroid Graves' disease with ophthalmopathy IS well known to be mediated via an autoimmune process. Wasnich et al. 10 postulated the association between Graves' disease and neck irradiation. Further case reports 5 ,9 have confirmed these findings and indicate its rarity. 
Autoimmune endocrine diseases may evolve over extended intervals. This is frequently seen in autoimmune thyroid disease, where the presence of thyroid antibodies may be the only evidence of the disease''; few of such patients progress to overt sex characteristics were normal. The skin was of normal texture and warmth, but pigmented, particularly in skin creases. Laboratory investigations showed Na 133 mmolll, K 4.7 mmolll, Cl 99 mmolll, CO 2 25 mmol/l, glycosylated haemoglobin 0.076 (normal 0.04-0.06), urinary 17-ketogenic steroids 33.6 !tmol/day (normal 14-55) and urinary 17-hydroxycorticosteroids 16 !tmol/day (normal 3-30). Plasma adrenocorticotrophic hormone (ACTH) was 113 pmolll (normal 2-22). A short tetracosactrin (Cortrosyn) test at 8 am revealed a normal basal cortisol, but an impaired cortisol response (Table 1) . Adrenal cortical, thyroid antimicrosomal, and parietal cell antibodies were positive. HLA type was B8 and OR3.
The patient was diagnosed as having 'compensated Addison's disease', that is she was still secreting sufficient cortisol by virtue of an elevated ACTH level. She was not treated with corticosteroids but advised to take them in the event of trauma or illness; frequent repeat visits were advised. Four months later she complained of lightheadedness and weight loss of 5 kg; blood pressure was 108/80 mmHg supine, 60/0 standing; serum Na 129 mmol/l, K 5.1 mmolll, plasma cortisol (8 am) 96 nmolll (normal 140-600). Steroid therapy was initiated with resolution of symptoms; she required a modest increase in insulin dosage thereafter. Subclinical (compensated) disease is common in autoimmune endocrine disease; normal function in the damaged gland is maintained through increased stimulatory hormones, e.g. subclinical hypothyroidism 1, Abnormal patterns of insulin secretion may be detected years before overt insulin-dependent diabetes (100M) becomes manifests. However, Addison's disease is rarely detected prior to the onset of symptoms. We report a case of asymptomatic, compensated Addison's disease in a patient with polyglandular autoimmune disease. 
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Case report
A 29-year-old Caucasian woman with 100M and a history of Graves' disease treated by thyroidectomy was referred to The Wellesley Hospital with a oneyear history of hyperpigmentation. She had returned from holiday the previous year with a dark tan which did not fade over the ensuing months, despite no further sun exposure. Her only complaint was that of mild evening fatigue. She denied weight loss, nausea, vomiting, or lightheadedness, She had had a spontaneous abortion at 6 weeks' gestation one year earlier; although her menses remained normal, she was unable to conceive again. She was currently taking only insulin and thyroxine (for post-thyroidectomy hypothyroidism).
Physical examination revealed a well-nourished, deeply pigmented young woman (height 170 em, weight 52.0 kg). Scalp hair was of normal texture. There was marked facial and buccal pigmentation. Ophthalmoscopic examination and visual fields were normal. The thyroid was not palpable with an old thyroidectomy scar. Heart rate was 78/min regular; supine blood pressure was 130/80 mmHg, with no postural change. Heart sounds were normal and the chest clear. There were no abnormal abdominal masses. External genitalia and secondary 
